Literature DB >> 14614677

Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults.

Hidehiko Takahashi1, Kazunori Oishi, Hiroyuki Yoshimine, Atsushi Kumatori, Kazuhiko Moji, Kiwao Watanabe, Hawa Nalwoga, Sitefano Buguruka Tugume, Anthony Kebba, Roy Mugerwa, Peter Mugyenyi, Tsuyoshi Nagatake.   

Abstract

Type-specific immunoglobulin G (IgG) to pneumococcal capsular polysaccharide (CPS) and opsonic activity against Streptococcus pneumoniae were evaluated in serum samples from 36 Ugandan adults with community-acquired pneumonia and 58 asymptomatic Ugandan adults with or without human immunodeficiency virus type 1 (HIV-1) infection. The levels of serum IgG to CPS were significantly higher in HIV-1-infected subjects than in HIV-uninfected subjects. Serum samples from HIV-1-infected subjects that had lower IgG titers demonstrated higher opsonic activity against type 3 (titers of 7) and type 9 (titers of 7-11) pneumococcal strains. Plasma HIV-1 load also correlated inversely with serum opsonic activity against these strains, and peripheral blood CD4+ lymphocyte numbers also tended to correlate with serum opsonic activity in asymptomatic HIV-1-infected adults. Our findings suggest that the opsonic activity of type-specific IgG is impaired in the serum of HIV-1-infected African adults, which may expose them to a serious risk of invasive pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614677     DOI: 10.1086/379511

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Reduced Treponema pallidum-Specific Opsonic Antibody Activity in HIV-Infected Patients With Syphilis.

Authors:  Christina M Marra; Lauren C Tantalo; Sharon K Sahi; Shelia B Dunaway; Sheila A Lukehart
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

Review 2.  Lung microbiome in human immunodeficiency virus infection.

Authors:  Homer L Twigg; George M Weinstock; Kenneth S Knox
Journal:  Transl Res       Date:  2016-07-18       Impact factor: 7.012

Review 3.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

Review 4.  HIV-1 and bacterial pneumonia in the era of antiretroviral therapy.

Authors:  Leopoldo N Segal; Barbara A Methé; Anna Nolan; Yoshihiko Hoshino; William N Rom; Rod Dawson; Eric Bateman; Michael D Weiden
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 5.  Co-infection subverts mucosal immunity in the upper respiratory tract.

Authors:  Rebeccah S Lijek; Jeffrey N Weiser
Journal:  Curr Opin Immunol       Date:  2012-06-02       Impact factor: 7.486

6.  C3b/iC3b deposition on Streptococcus pneumoniae is not affected by HIV infection.

Authors:  Catherine Hyams; Jerry C H Tam; Jeremy S Brown; Stephen B Gordon
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

Review 7.  Impact of antiretroviral therapy on lung immunology and inflammation.

Authors:  Homer L Twigg; Kenneth S Knox
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

8.  HIV-Related Lung Disorders.

Authors:  Homer L Twigg; Kenneth S Knox
Journal:  Drug Discov Today Dis Mech       Date:  2007

Review 9.  Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development.

Authors:  Richard Malley
Journal:  J Mol Med (Berl)       Date:  2010-01-05       Impact factor: 4.599

10.  Interleukin-17A mediates acquired immunity to pneumococcal colonization.

Authors:  Ying-Jie Lu; Jane Gross; Debby Bogaert; Adam Finn; Linda Bagrade; Qibo Zhang; Jay K Kolls; Amit Srivastava; Anna Lundgren; Sophie Forte; Claudette M Thompson; Kathleen F Harney; Porter W Anderson; Marc Lipsitch; Richard Malley
Journal:  PLoS Pathog       Date:  2008-09-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.